{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:44:32Z","timestamp":1791045872621,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.eururo.2020.12.032","type":"journal-article","created":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T15:21:54Z","timestamp":1609600914000},"page":"492-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men"],"prefix":"10.1016","volume":"79","author":[{"given":"Cosimo","family":"De Nunzio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bschleipfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Gravas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Oelke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Peyronnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Tutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gommert","family":"van Koeveringe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Madersbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.12.032_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/nau.23897","article-title":"The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction","volume":"38","author":"D\u2019Ancona","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0010","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003193.pub3","article-title":"Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults","volume":"4","author":"Alhasso","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2020.12.032_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2019.02.005","article-title":"The relative efficacy and safety of mirabegron and onabotulinumtoxinA in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis","volume":"127","author":"Lozano-Ortega","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.12.032_bib0025","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0030","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2019.09.020","article-title":"Multicriteria decision analysis applied to the clinical use of pharmacotherapy for overactive bladder symptom complex","volume":"6","author":"Chapple","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2020.12.032_bib0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1185\/03007995.2014.968704","article-title":"Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data","volume":"31","author":"Hakimi","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.eururo.2020.12.032_bib0040","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/nau.23170","article-title":"Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015)","volume":"36","author":"Apostolidis","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0045","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1002\/nau.24055","article-title":"How can we better manage drug-resistant OAB\/DO? ICI-RS 2018","volume":"38","author":"Chermansky","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urols.2014.12.003","article-title":"Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder","volume":"26","author":"Wang","year":"2015","journal-title":"Urol Sci"},{"key":"10.1016\/j.eururo.2020.12.032_bib0055","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0060","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2020.12.032_bib0065","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","article-title":"Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)","volume":"203","author":"Kaplan","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.urology.2018.03.038","article-title":"Mirabegron 25 mg monotherapy is safe but less effective in male patients with overactive bladder and bladder outlet obstruction","volume":"117","author":"Liao","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.12.032_bib0075","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/nau.23935","article-title":"Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies","volume":"38","author":"Matsukawa","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-016-0165-3","article-title":"The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with \u03b11-adrenergic receptor blocker monotherapy: prospective analysis of elderly men","volume":"16","author":"Matsuo","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11255-012-0343-5","article-title":"\u03b23-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men","volume":"45","author":"Otsuki","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0090","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/nau.23852","article-title":"Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study","volume":"38","author":"Shin","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0095","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018802","article-title":"The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis","volume":"99","author":"Su","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.eururo.2020.12.032_bib0100","doi-asserted-by":"crossref","unstructured":"Takahashi S, Kato D, Tabuchi H, Uno S. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: a Japanese post-marketing study. Low Urin Tract Symptoms. In press. https:\/\/doi.org\/10.1111\/luts.12335.","DOI":"10.1111\/luts.12335"},{"key":"10.1016\/j.eururo.2020.12.032_bib0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756287217702797","article-title":"Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies","volume":"9","author":"Tubaro","year":"2017","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0110","first-page":"1559","article-title":"Efficacy of tadalafil once daily versus fesoterodine in the treatment of overactive bladder in older patients","volume":"19","author":"Dell\u2019atti","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.eururo.2020.12.032_bib0115","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/iju.13489","article-title":"Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a urodynamic-based study","volume":"25","author":"Matsukawa","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0120","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/nau.24285","article-title":"A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT study)","volume":"39","author":"Yamanishi","year":"2020","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0125","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1464-410X.2010.09205.x","article-title":"A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder","volume":"106","author":"Giuliano","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.12.032_bib0130","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.eururo.2011.08.005","article-title":"Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results of an international randomized, double-blind, placebo-controlled trial","volume":"60","author":"Porst","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0135","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.12.032_bib0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0145","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0150","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.eururo.2011.07.002","article-title":"Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Cruz","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bju.13110","article-title":"Botulinum toxin (onabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes","volume":"116","author":"Habashy","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.12.032_bib0160","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/nau.23196","article-title":"Long-term compliance and results of intravesical botulinum toxin A injections in male patients","volume":"36","author":"Rahnama\u2019i","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0165","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JU.0000000000000525","article-title":"Treatment response and complications after intradetrusor onabotulinumtoxinA injection in male patients with idiopathic overactive bladder syndrome","volume":"203","author":"Mateu Arrom","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0170","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2019.08.054","article-title":"Predictors of poor response and adverse events following botulinum toxin-A for refractory idiopathic overactive bladder","volume":"135","author":"Abrar","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.12.032_bib0175","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","article-title":"Onabotulinum toxin A injections in men with refractory idiopathic detrusor overactivity","volume":"123","author":"Faure Walker","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.12.032_bib0180","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00192-020-04429-8","article-title":"Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis","volume":"31","author":"Wang","year":"2020","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.eururo.2020.12.032_bib0185","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00345-018-2296-5","article-title":"Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder","volume":"36","author":"Leroux","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0190","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.eururo.2017.11.002","article-title":"Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature","volume":"73","author":"Tutolo","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0195","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11255-018-1843-8","article-title":"Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men","volume":"50","author":"Nguyen","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0200","unstructured":"Comparative study between behavior therapy and behavior therapy plus mirabegron in sexually active men with OAB symptoms. Full text view. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04420533."},{"key":"10.1016\/j.eururo.2020.12.032_bib0205","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/bju.15020","article-title":"Efficacy of vibegron, a novel \u03b23-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study","volume":"125","author":"Yoshida","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.12.032_bib0210","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JU.0000000000000807","article-title":"International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR","volume":"204","author":"Staskin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0215","unstructured":"Study to evaluate the efficacy, safety and tolerability of vibegron in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH). Full text view. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03902080?cond=vibegron&draw=2&rank=3."},{"key":"10.1016\/j.eururo.2020.12.032_bib0220","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/nau.23088","article-title":"How does lower urinary tract dysfunction (LUTD) affect sexual function in men and women? ICI-RS 2015-Part 2","volume":"36","author":"Apostolidis","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11255-016-1277-0","article-title":"Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study","volume":"48","author":"Chancellor","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0230","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1111\/bph.12502","article-title":"TRP channels in lower urinary tract dysfunction","volume":"171","author":"Franken","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0235","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00345-018-2268-9","article-title":"Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis","volume":"36","author":"Chen","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0240","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11934-013-0363-4","article-title":"Mirabegron for male lower urinary tract symptoms","volume":"14","author":"Suarez","year":"2013","journal-title":"Curr Urol Rep"},{"issue":"7","key":"10.1016\/j.eururo.2020.12.032_bib0245","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/ijcp.12194","article-title":"Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies","volume":"67","author":"Nitti","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2020.12.032_bib0250","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.eururo.2020.12.032_bib0255","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"73","author":"Nambiar","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0260","article-title":"Guidelines on the management of male lower urinary tract symptoms benign prostatic obstruction (BPO)","author":"Gravas","year":"2015","journal-title":"European Association of Urology"},{"key":"10.1016\/j.eururo.2020.12.032_bib0265","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II) [figure presented]","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0270","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euf.2017.08.008","article-title":"Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study","volume":"3","author":"Gibson","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2020.12.032_bib0275","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bju.13068","article-title":"Safety and efficacy of mirabegron as \u201cadd-on\u201d therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study)","volume":"116","author":"Yamaguchi","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.12.032_bib0280","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2174\/1389450116666150806124345","article-title":"The current indications and the benefits of combining a \u03b23-agonist with an anticholinergic for the treatment of OAB","volume":"16","author":"de Nunzio","year":"2015","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.eururo.2020.12.032_bib0285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41391-018-0039-8","article-title":"Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction","volume":"21","author":"Samarinas","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2020.12.032_bib0290","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment (figure presented)","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0295","doi-asserted-by":"crossref","first-page":"712","DOI":"10.23736\/S0393-2249.20.03762-5","article-title":"The urothelium, the urinary microbioma and men LUTS: a systematic review","volume":"72","author":"Lombardo","year":"2020","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0300","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-5347(05)63949-3","article-title":"The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction","volume":"169","author":"de Nunzio","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0305","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2008.02.017","article-title":"Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia","volume":"54","author":"Oelke","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0310","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0315","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2011.03.054","article-title":"The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update","volume":"60","author":"Athanasopoulos","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0320","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000357626","article-title":"Prediction of persistent storage symptoms after transurethral resection of the prostate in patients with benign prostatic enlargement","volume":"93","author":"Choi","year":"2014","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.12.032_bib0325","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.juro.2014.12.095","article-title":"Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate?","volume":"193","author":"Antunes","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0330","first-page":"75","article-title":"Clinical efficacy of transurethral resection of the prostate combined with oral anticholinergics or botulinum toxin\u2014a injection to treat benign prostatic hyperplasia with overactive bladder: a case\u2013control study","volume":"12","author":"Allameh","year":"2020","journal-title":"Clin Pharmacol Adv Appl"},{"key":"10.1016\/j.eururo.2020.12.032_bib0335","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.euf.2019.04.006","volume":"5","author":"Lewis","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2020.12.032_bib0340","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.06.004","article-title":"Diagnostic assessment of lower urinary tract symptoms in men considering prostate surgery: a noninferiority randomised controlled trial of urodynamics in 26 hospitals","volume":"78","author":"Drake","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0345","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.urology.2015.03.033","article-title":"Effect of detrusor overactivity on functional outcomes after holmium laser enucleation of the prostate in patients with benign prostatic obstruction","volume":"86","author":"Jeong","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.12.032_bib0350","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.urology.2014.06.027","article-title":"Detrusor overactivity does not predict bothersome storage symptoms after photoselective vaporization of the prostate with lithium triborate laser","volume":"84","author":"Dybowski","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2020.12.032_bib0355","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/nau.24041","article-title":"Metabolic syndrome and smoking are associated with persistence of nocturia after transurethral resection of the prostate","volume":"38","author":"De Nunzio","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2020.12.032_bib0360","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/MOU.0000000000000249","article-title":"Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?","volume":"26","author":"Cornu","year":"2016","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2020.12.032_bib0365","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2015.07.054","article-title":"A multicenter randomized noninferiority trial comparing GreenLight-Xps laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study","volume":"69","author":"Thomas","year":"2016","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820310186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820310186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:08:10Z","timestamp":1759583290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283820310186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0302283820310186"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.12.032","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}